Esquire Financial director Anthony Coelho sells $1.47 million in stock

Esquire Financial director Anthony Coelho sold 11,600 shares on October 29, 2026, for about $1.47 million at $126.9987 per share; he retained 55,765 directly held shares, plus 12,910 through a trust and 36,000 through an IRA. The article also reports Q3 adjusted EPS of $2.12 versus the $1.89 estimate and revenue of $61.39 million, with the August 1 Signature Bank merger contributing to results. Keefe, Bruyette & Woods raised its price target to $135 from $128 while maintaining a Market Perform rating; organic loan growth was 20% annualized last quarter, excluding Signature.

Analysis

The director’s sale is a weak standalone bearish signal: he retains substantial reported direct and indirect exposure, and the filing does not establish whether the sale was discretionary or pre-planned. The more consequential issue is whether recent earnings strength is repeatable. Organic loan growth and core pre-provision revenue are better indicators of underlying momentum than merger contribution or lower provision expense; rapid lending growth can also take several quarters to reveal weaker underwriting. Scheduled vesting creates a possible future supply overhang, but vesting is not equivalent to selling.

Near term, the sale may cap sentiment after a strong run, but it does not by itself invalidate the operating trend. Over 1–3 months, monitor loan growth, deposit/funding costs, credit quality, and the next guidance update for evidence that growth is converting into recurring earnings. Over 6–18 months, merger integration and seasoning of newly originated loans matter more than this transaction. The promotional “undervalued” label and a broker target are not sufficient valuation evidence; absent peer multiples, funding data, and credit vintage performance, risk/reward is difficult to underwrite. The contrarian point is that investors may overread a single insider sale while underweighting the lag between loan growth and credit losses.

Key Decisions for Investors

• Do not short ESQ solely on this sale; the reported retained holdings and lack of information on transaction intent weaken its signal.
• Avoid chasing the post-results strength at current levels. Consider a staged long only on a pullback or after another report confirms organic growth is translating into recurring core earnings.
• Before adding, verify the next quarter’s organic loan growth, deposit and funding costs, core pre-provision revenue, and credit performance by loan vintage. Treat scheduled vesting as a potential—not certain—source of insider selling.
• Falsify the constructive thesis if organic growth materially slows, funding costs squeeze earnings, or net charge-offs/provisions rise as recent loan cohorts season; reassess if management attributes earnings momentum mainly to merger effects or reserve timing.